News
People think Corona lager is the cause of the coronavirus outbreak
The Manc -
30th January 2020
The Manc -
30th January 2020 News
Transfers: Manchester United reportedly in the race for Rafael Leao as asking price is revealed
Danny Jones
In the latest transfer news coming out of Manchester, Man United are reportedly set to make the first move in an effort to sign Serie A star Rafael Leao after AC Milan are said to have ‘offered’ the wantaway winger to Premier League rivals Arsenal.
After being linked with MUFC on and off in the past, this could shape up to be a tasty tug of war if all rumours are to be believed.
United fans will be hoping this isn’t just another Viktor Gyökeres or even a Wesley Sneijder situation, especially since Leao and his agent have made it clear that he is ready to leave the Italian giants after seven years, with The Times stating that he’s already been offered to the newly crowned champions.
But a recent interview by Leao may have pricked up ears over at Old Trafford and Carrington:
Speaking to London-born and now Manchester-headquartered (interesting…) streetwear and jewellery brand Cernucci on their new podcast, the Portuguese international confessed to presenter Fred Buckley that he spent much of his childhood watching Man United, and still does to this day.
ADVERTISEMENT
While he also admitted he likes Arsenal, adding even more fuel to the fire of the links with the Gunners, he also named Cristiano Ronaldo as his idol; either way, the ‘Rossoneri’ are believed to be asking for between £43-50 million for the former Sporting and Lille player.
A teammate of his with the national squad and having starred for major European sides, winning silverware – a Serie A title and Italian Super Cup, as well as a UEFA Nations League with Portugal – he’s evidently looking to try and emulate his fellow compatriots’ success moving forward.
ADVERTISEMENT
Now 26 years old, he’s at a crucial juncture in his career, and despite being criticised for his work rate and efforts off the ball at times, not to mention blowing somewhat hot and cold in and around a fair few injury problems, the next big money move feels almost inevitable as he approaches his ‘prime’ years.
With multiple reports in Italy and across Europe claiming that Man United are ready to chase Leao as one of various transfer targets this summer, it may come down to a case of who pursues him hardest: INEOS, Arsenal, or perhaps another big continental team.
🚨‼️ Rafael Leão booed by San Siro after being substituted off against Udinese. (@LucaManinetti) pic.twitter.com/AmBsxHGVKH
— EuroFoot (@eurofootcom) April 11, 2026
As you can see, many Milan fans have seemingly turned on him already after he made his plans to depart rather publicly, which has also seen him pop up on the radar of several other Champions League competitors this summer.
One such alternative suitor outside of English football is Galatasaray, with multiple Italian and Turkish outlets claiming that the club are the only team to be drawing up a ‘formal proposal’ thus far.
Journalist Matteo Moretto states that no official offer has been made as yet; he is also one of numerous sources who have revealed that Man United’s deal to sign Brazilian midfielder Ederson – also currently plying his trade in Italy – is now effectively ‘done’.
As for the mercurial forward, can you see Rafa Leao becoming a Red Devil?
Read more:
- Bernardo Silva shares hilarious X-rated clash with John Stones before they were teammates
- All you need to know about the ICC Women’s T20 World Cup before it comes to Manchester
- Stockport County are hosting huge World Cup screenings at Edgeley Park
For all the latest news, events and goings on in Greater Manchester, subscribe to The Manc newsletter HERE.
Featured Images — Cernucci Podcast (screenshot via YouTube)/LHC88 (via Wikimedia Commons)
News
NHS rolls out new ‘life-extending’ ovarian cancer drug for first time in 20 years
Emily Sergeant
The NHS has approved a new ovarian cancer treatment for the first time in two decades.
From today, hundreds of women with ‘hard-to-treat’ ovarian cancer could benefit from a new life-extending drug on the NHS called mirvetuximab soravtansine, and it will be offered to patients living with whose disease has unfortunately stopped responding to standard chemotherapy treatments, providing them with new hope of extra time to live.
The rollout of the drug on the NHS follows a major global clinical trial involving eight NHS hospitals, which showed that the treatment delayed cancer progression and prolonged survival – with patients living 16.5 months on average compared to 12.8 months with chemotherapy.
One patient said the treatment enabled her to get on with life ‘rather than spending it in bed recovering from the side effects of chemotherapy’.
So, how does it work then?
Well, the drug combines a ‘homing’ antibody with a cancer-killing medicine – often described by scientists as a ‘biological missile’ or ‘trojan horse’ therapy – and it works by attaching to ovarian cancer cells that have a protein called folate receptor alpha (FRα) on their surface, before releasing a cancer-killing molecule which destroys the cell from within.
The treatment is given intravenously, via a drip, over two to four hours, once every three weeks.
The drug may also have ‘more tolerable’ side effects than traditional chemotherapy, with the treatment aimed more precisely at cancer cells than chemotherapy.
The NHS estimates up to 400 patients in England each year could benefit.
“This represents the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades, commented Professor Ruth Plummer, who is the NHS’s national clinical lead for cancer drugs.
Read more:
- Groundbreaking new ‘rapid’ jab to treat 14 different cancer types now available on NHS
- NHS to offer thousands of people access to ‘life-extending’ cancer drug
- Five-minute ‘super jab’ to treat 15 different types of cancer rolled-out on NHS
“We’re delighted it will now offer hundreds of women much-needed hope of precious extra time with their loved ones.
“It is part of a growing wave of more targeted cancer therapies which, by homing in on specific features of cancer cells, are helping us improve patients’ lives.”
Featured Image – Stephen Andrews (via Unsplash)
More News
Audio
Clint Boon takes us around Manchester's iconic Deaf Institute
Eats